Nephrol Dial Transplant. 2022 Sep 15:gfac271. doi: 10.1093/ndt/gfac271. Online ahead of print.
ABSTRACT
BACKGROUND: Calciprotein particles (CPP), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction, and inflammation. We hypothesized that phosphate binder therapy with sucroferric oxyhydroxide (SO) would reduce endogenous CPP levels, and attenuate pro-calcific and pro-inflammatory effects of patient serum towards human vascular cells in vitro.
METHODS: This secondary analysis of a randomized, controlled cross-over study compared the effect of two-week phosphate binder washout with high-dose (2000 mg/d) and low-dose (250 mg/d) SO therapy in 28 hemodialysis patients on serum CPP levels, inflammatory cytokine/chemokine arrays, and human aortic smooth muscle cell (HASMC) and coronary artery endothelial cell (HCAEC) bioassays.
RESULTS: In our cohort (75% male, 62 ± 12 years) high-dose SO reduced primary (amorphous) and secondary (crystalline) CPP levels [-62 (-76 to -44)%, P < 0.0001 and -38 (-62 to -0.14)%, P < 0.001, respectively] compared with washout. Nine of 14 plasma cytokines/chemokines significantly decreased with high-dose SO, with consistent reductions in Interleukin-6 (IL-6) and IL-8. Exposure of HASMC and HCAEC cultures to serum of SO-treated patients reduced calcification and markers of activation (IL-6, IL-8, and vascular cell adhesion protein 1) compared with washout. Serum-induced HASMC calcification and HCAEC activation was ameliorated by removal of the CPP-containing fraction from patient sera. Effects of CPP removal were confirmed in an independent cohort of chronic kidney disease patients.
CONCLUSIONS: High-dose SO reduced endogenous CPP formation in dialysis patients and yielded serum with attenuated pro-calcific and inflammatory effects in vitro.
PMID:36107466 | DOI:10.1093/ndt/gfac271
